Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study

Who May Qualify: - Severe haemophilia A (FVIII activity \[FVIII:C\] \<1%) according to medical history - Male patients at least 12 years of age - Previous treatment with any FVIII product(s) for at least 150 exposure days - On regular prophylaxis with emicizumab for at least 1 month prior to a scheduled major elective surgery requiring FVIII treatment - Freely given written willing to sign a consent form of the patient, or parent/legal representative where applicable, obtained in accordance with local regulations Who Should NOT Join This Trial: - Coagulation disorder other than haemophilia A - Present or past FVIII inhibitor (≥0.6 Bethesda units \[BU\]/mL) according to medical history - Severe liver or kidney disease (alanine aminotransferase \[ALT\] and/or aspartate aminotransferase \[AST\] levels \>5 times the upper limit of normal; or creatinine \>120 μmol/L) - Known hypersensitivity to Nuwiq's active substance or its excipients (sucrose, sodium chloride, calcium chloride dihydrate, arginine hydrochloride, sodium citrate dihydrate, poloxamer 188) - Already had surgery in this study - Current participation in another interventional clinical trial - Treatment with any investigational medicinal product (IMP) within 30 days prior to screening visit Always talk to your doctor about whether this trial is right for you.